Search Results

Biosensors’ Iconic Microcatheter Evaluated in BIOMICS Pivotal Trial in United Kingdom

April 5, 2022—Biosensors International Group, Ltd. announced the enrollment of the first patient in BIOMICS, a prospective, multicenter evaluation of the safety and effectiveness of the Biosensors microcatheter in patients undergoing percutaneous coronary intervention for the treatment of chronic total occlusions (CTOs).

Shockwave Initiates All-Female EMPOWER CAD Coronary IVL Study

September 19, 2022—Shockwave Medical, Inc. announced that the company has initiated EMPOWER CAD, a coronary artery disease (CAD) intervention study consisting of all female patients to determine whether the positive results from earlier coronary studies of intravascular lithotripsy (IVL) with the Shockwave C2 coronary IVL catheter (which showed similar safety outcomes across both sexes) can be replicated in an expanded, real-world population of female patients with severely calcified coronary lesions.

Shockwave EMPOWER CAD Evaluates IVL-First Strategy in Female Patients

May 20, 2025—Shockwave Medical, Inc., part of Johnson & Johnson MedTech, announced the 30-day primary endpoint results of the EMPOWER CAD study.

Shockwave Launches C²⁺ IVL Catheter Internationally, Commences All-Female EMPOWER CAD Study

May 15, 2023—Shockwave Medical, Inc. announced the full commercial availability in select international markets of the Shockwave C2+ coronary intravascular lithotripsy (IVL) catheter.

Johnson & Johnson Launches Shockwave C2 Aero Coronary IVL Catheter

May 12, 2026—Johnson & Johnson announced the global launch of its Shockwave C2 Aero coronary intravascular lithotripsy IVL catheter for the treatment of calcified coronary artery disease (CAD).